NIRAPARIB AND ABIRATERONE ACETATE PLUS PREDNISONE TO IMPROVE CLINICAL OUTCOMES IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND HRR ALTERATIONS

The present disclosure relates to niraparib and abiraterone acetate, plus prednisone or prednisolone; for use in a method of improving the efficacy of treatment of metastatic castration-resistant prostate cancer (mCRPC) in a patient with DNA-repair anomalies, in particular for improving the median r...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	LOPEZ-GITLITZ Angela Mennicke, LI Susan Xuemei, URTISHAK Karen Ann, FRANCIS Peter, A DEL CORRAL Adam, A HUTNICK Natalie, P GORMLEY Michael, WANG Guilin, ZHANG Ke, THOMAS Shibu
Format:	Patent
Sprache:	eng ; spa
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present disclosure relates to niraparib and abiraterone acetate, plus prednisone or prednisolone; for use in a method of improving the efficacy of treatment of metastatic castration-resistant prostate cancer (mCRPC) in a patient with DNA-repair anomalies, in particular for improving the median radiographic progression-free survival (rPFS). La presente descripción se relaciona con niraparib y acetato de abiraterona, más prednisona o prednisolona; para usar en un método de mejora de la eficacia del tratamiento del cáncer de próstata metastásico resistente a la castración (mCRPC) en un paciente con anomalías de reparación del ADN, en particular para mejorar la mediana de supervivencia libre de progresión radiográfica (rPFS).